A coloring compound comprises a triphenylmethane structure having specific substituents.

Electrowetting element including a compound comprising a plurality of colorant moieties and a linker. The plurality of colorant moieties includes a first colorant moiety having a first net dipole and a second colorant moiety having a second net dipole. The plurality of colorant moieties are linked by and disposed around the linker so that the first net dipole and the second net dipole at least partially cancel each other.

The subject of the present invention is symmetric or dissymetric azomethine direct dyes comprising at least one pyrazolopyridine unit of formula (I), a composition comprising said dyes, a process for treating keratin fibers using said dyes, a process for preparing these compounds, synthesis intermediates and a kit. In which formula (I) X, Y.sub.1, Y.sub.2, Z.sub.1, and R.sub.1 to R.sub.5 are as defined in the description.

##STR00001##

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.

A water-based ink for ink-jet recording includes dyes and water. The dyes include a blue dye having a hue angle of 220 to 280; a yellow dye having a hue angle of 70 to 120; and a copper phthalocyanine dye. A mass ratio (C/B) of a content (C) of the copper phthalocyanine dye to a content (B) of the blue dye in an entire amount of the water-based ink is equal to or more than 0.5, and a total content of the dyes in the entire amount of the water-based ink is equal to or more than 6% by mass.

A compound represented by specific chemical formula, a core including the same, a core-shell dye including a shell surrounding the core, a photosensitive resin composition including the same, and a color filter manufactured using the photosensitive resin composition are disclosed.

In an ultraviolet-curable resin composition for an optical fiber coating, the polarity parameter E.sub.T(30) of the resin composition is 47 to 61.

A leuco polymer comprising a polyethylenimine and at least one leuco moiety covalently bound to the polyethylenimine, wherein the polyethylenimine comprises three or more amine nitrogen atoms and 1 mol. % or more of amine hydrogen atoms in the polyethylenimine are replaced with a moiety selected from the group consisting of 2-hydroxypropyl, 1-hydroxypropane-2-yl, and polyalkoxy groups. Methods of making the leuco polymer, laundry care compositions comprising the leuco polymer and methods of treating textiles with such laundry care compositions.

Electrowetting apparatus including at least one compound selected from the group consisting of: ##STR00001##
wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently an alkyl group. In examples a fluid includes a dye compound selected from: ##STR00002##

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.